EMEA-000802-PIP01-09 - paediatric investigation plan

anti-BAFF monoclonal antibody (LY2127399)

Key facts

• Active substance:
  anti-BAFF monoclonal antibody (LY2127399)
• Therapeutic area:
  Oncology
• Decision number:
  P/252/2010
• PIP number:
  EMEA-000802-PIP01-09
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  • Treatment of chronic autoimmune arthritis
  • Treatment of multiple sclerosis
• Route(s) of administration:
  Subcutaneous use
• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  26/11/2010
• Compliance check done:
  No

Decision

P/252/2010: EMA decision of 26 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for anti-BAFF monoclonal antibody (LY2127399), (EMEA-000...

Adopted Reference Number: EMA/716619/2010